Cochlear Limited risk profile
41 Elevated one input has moved against it
Measured 1 September 2026 from OC5's filed statements. Recomputed nightly.
41 (Elevated), driven by Market expectation at 82, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 82 | Acute | Volatile | Drawdown from the 52-week high — 50.0% |
| Operating pressure | 45 | Elevated | Worsening | Costs outgrowing revenue — +1.5 percentage points |
| Cash conversion | Reads operating_cashflow, capital_expenditure, free_cashflow, net_income and revenue. No reading is stored for this company. | |||
| Leverage and coverage | 6 | Contained | Stable | Current ratio — 2.35x |
| Competitive position | 42 | Elevated | Stable | R&D-intensity gap against peers — -5.7 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Cochlear Limited